Impact BioMedical completes 1-for-12.62 reverse stock split effective September 23, 2026

IMPACT BIOMEDICAL INC.

Reverse split ratio is 1-for-12.62, effective 12:01 A.M. EST on September 23, 2026; IBO began trading split-adjusted on NYSE American.
Outstanding shares fell from about 107.8 million to about 8.6 million; authorized shares, $0.001 par value, and voting rights were unchanged.
New CUSIP is 45259L304; Equiniti Transfer & Trust Company is exchange agent; no fractional shares were issued, with fractional holders receiving one full share.
Board approved reverse split on November 24, 2025, and majority stockholders approved it on December 30, 2025, with CEO given discretion on ratio.
Nevada Secretary of State clerical error delayed the file-stamped Amendment until October 6, 2026, after effectiveness on September 23, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.